EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at
Experience Project.
Joined: Mar 22, 2007 Posts: 407 Location: Durango, Co
Posted: Tue May 05, 2009 2:24 pm Post subject: Ocrelizumab
I was going through the clinical trials list and saw that Ocrelizumab is, or is still recruiting for phase 2. I'm wondering if this is really just Rituxan with a more complicated name or is this a way to get around the financial loss of a soon to expire patent on Rituxan? They must have tweaked it more than just the name.
Lars
I don't have the info at hand, but I think Ocrelizumab targets a different protein on B-cells. I think I also read somewhere that it may not have some of the toxic side effects of Rituxan.
Ocrelizumab is a humanized monoclonal anti-CD20 antibody constructed with recombinant DNA techniques and designed to selectively target CD20 B cells. (Rituxan is a "chimeric murine-human monoclonal antibody".) In vitro characterization of ocrelizumab demonstrated enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and reduced complement-dependent cytotoxicity (CDC) as compared with rituximab. Ocrelizumab binds to a different, but overlapping, epitope of the extracellular domain of CD20 as compared with rituximab.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum
We encourage you to also visit our Multiple Sclerosis support community on Experience Project.
Experience Project is a vast and powerful community where people connect anonymously through life experiences. It's made by the same people who built This is MS,
on the premise that no single life experience-- like having MS-- defines a person. EP now covers over 5 million true stories about every possible life experience. Find and share yours!
Forum FAQ
Search
Usergroups
Profile
Log in
